Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for EDP-978, the Company’s KIT inhibitor in development for the treatment of mast cell-mediated, Type 2 immune diseases, will be presented in two poster presentations at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting being held February 27 – March 2, 2026 in Philadelphia, PA. Details of the presentations are as follows: Abstract Title: Discovery of a Potent and Selective KIT inhibitor for Treatment of Mast Cell-Mediated Diseases Date: Friday, February 27, 2026 Time: 2:45 – 3:45 PM EST Poster Number: 104 Session: Allergic Skin Diseases Location: Convention Center, Level 2, Hall E Presenter: Tessa Cressey, Ph.D. Abstract Title: EDP-978, a Potent KIT Inhibitor, Demonstrated Dose-Dependent Target-Engagement and a Favorable Pharmacokinetic Profile with Once-Daily Dosing Potential in Humans Date: Friday, February 27, 2026 Time: 2:45 – 3:45 PM EST Poster Number: 038 Session: Allergic Skin Diseases Location: Convention Center, Level 2, Hall E Presenter: Yang Li, Ph.D. Abstracts are available in an online supplement to The Journal of Allergy and Clinical Immunology (JACI) platform here . Further information about AAAAI 2026 can be found here . Posters will be available on Enanta’s website here after presentations are held on February 27, 2026. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET ® (U.S.) and MAVIRET ® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. Contacts Media and Investors Contact: Jennifer Viera 617-744-3848 jviera@enanta.com